The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1541
ISSUE1541
February 26, 2018
Once-Monthly Subcutaneous Buprenorphine (Sublocade) for Opioid Use Disorder
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Once-Monthly Subcutaneous Buprenorphine (Sublocade) for Opioid Use Disorder
February 26, 2018 (Issue: 1541)
The FDA has approved a subcutaneous (SC)
extended-release formulation of the mu-opioid
receptor partial agonist and kappa-opioid receptor
antagonist buprenorphine (Sublocade – Indivior)
for once-monthly treatment of moderate to severe
opioid...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.